Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer

DISEASE CHARACTERISTICS:

* Diagnosis of metastatic cancer
* Tumor overexpresses p53 as assessed by immunohistochemistry (i.e., ≥ 5% tumor cells stain positive for p53)

  * Biopsy must be available to evaluate p53 expression
* Human leukocyte antigens 0201 (HLA-A\*0201) positive
* Progressive or recurrent disease after prior standard therapy for metastatic disease

  * Patients with melanoma or renal cell cancer must have previously received aldesleukin
  * Patients with other histologies, not including hematologic malignancies, must have previously received first-line and second-line or higher systemic standard therapy (or effective salvage chemotherapy regimens)

PATIENT CHARACTERISTICS:

* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
* Life expectancy \> 3 months
* Absolute neutrophil count \> 1,000/mm\^3
* White blood cell (WBC) \> 3,000/mm\^3
* Platelet count \> 100,000/mm\^3
* Hemoglobin \> 8.0 g/dL
* Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤ 2.5 times upper limit of normal
* Serum creatinine ≤ 1.6 mg/dL
* Total bilirubin ≤ 2.0 mg/dL (\< 3.0 mg/dL in patients with Gilbert's syndrome)
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for 4 months after completion of study treatment
* Patients who have previously received ipilimumab or ticilimumab must have a normal colonoscopy with normal colonic biopsies
* Human immunodeficiency virus (HIV) antibody negative
* Hepatitis B antigen and hepatitis C antibody negative (unless antigen negative)
* No primary immunodeficiency (e.g., severe combined immunodeficiency disease)
* No active systemic infections
* No history of severe immediate hypersensitivity reaction to any of the agents used in this study
* No coagulation disorders
* No myocardial infarction or cardiac arrhythmias
* No history of coronary revascularization
* No obstructive or restrictive pulmonary disease
* No contraindications for high-dose aldesleukin administration
* Left ventricular ejection fraction (LVEF) ≥ 45% in patients meeting any of the following criteria:

  * History of ischemic heart disease,
  * chest pain,
  * or clinically significant atrial and/or ventricular arrhythmias including, but not limited to, atrial fibrillation,
  * ventricular tachycardia,
  * or second- or third-degree heart block
  * At least 60 years of age
* Forced expiratory volume 1 (FEV\_1) \> 60% predicted in patients meeting any of the following criteria:

  * Prolonged history of cigarette smoking (\> 20 pack/year within the past 2 years)
  * Symptoms of respiratory dysfunction
* No other major medical illness of the cardiovascular,

  * respiratory,
  * or immune system

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* Recovered from prior therapy
* More than 4 weeks since prior and no concurrent systemic steroid therapy
* More than 4 weeks since other prior systemic therapy
* More than 6 weeks since prior ipilimumab